Washington (PRWEB) April 15, 2014
Research that resulted in the first stem cells that are pluripotent—those that have the potential to differentiate into almost any cell in the body—will be the backdrop for a discussion about trends in regulation in the field of regenerative medicine at the DIA 2014 50th Annual Meeting, June 15 to 19 in San Diego.
Chaired by Shinji Miyake, professor of clinical research for the Keio University School of Medicine in Japan, the session “Pioneering Regenerative Medicine: Trends in Regulations for New Therapy” will introduce the world’s first clinical research of induced pluripotent stem (iPS) cell products, conducted in Japan, and review updated regulatory guidance to bring regenerative medicine to patients who need healthy tissue or organs. The session will be held June 16 at 8:30 a.m. in the San Diego Convention Center.
iPS cells are stem cells that can be generated directly from adult cells. These cells can multiply indefinitely and represent a single source of cells, such as heart, neural, pancreatic and liver, that can be used to replace damaged cells.
In 2006, Japanese physician and researcher Shinya Yamanaka led a team to generate iPS cells from adult mouse tissue using gene therapy. This work led to a Nobel Prize in Physiology or Medicine in 2012 for the discovery that mature cells can be reprogrammed to become pluripotent.
“We are honored to host pioneers of this unique field of medicine at the DIA Annual Meeting to share their experiences in the planning of the first clinical research of iPS cell products—which have the ability to enhance research worldwide,” said Barbara L. Kunz, DIA global chief executive. “Their expert knowledge of issues and solutions in the application of the regenerative therapies will benefit all who advocate for and drive innovative medicine.”
The session will also feature a presentation about the application of iPS cells to retinal diseases by Masayo Takahashi, project leader for the RIKEN Center for Developmental Biology in Japan, along with a European Medicines Agency (EMA) presentation by Dariusz Sladowski, researcher and member of the Committee for Advanced Therapies at EMA.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Pa., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit http://www.diahome.org.
ABOUT DIA’s 2014 50th ANNUAL MEETING: Celebrate the Past – Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products. The meeting aims to foster innovation that will lead to the development of safe and effective medical products and therapies for patients. For more information, visit http://www.diahome.org/dia2014.